Analysis of three outcome measures in moderate to severe psoriasis: A registry-based study of 2450 patients

British Journal of Dermatology

Volumn 166, Issue 4, 2012, Pages 797-802

  Norlin, J M ^a,b   Steen Carlsson, K ^b,c   Persson, U ^b,d   Schmitt Egenolf, M ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CORRELATION ANALYSIS; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; EUROPEAN QUALITY OF LIFE 5 DIMENSIONS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; SCORING SYSTEM; SWEDEN;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; REGISTRIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84859163285     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10778.x     Document Type: Article

References (37)

1. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
2. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-30.
3. Gupta MA, Gupta AK,. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846-50.
4. Schmitt JM, Ford DE,. Role of depression in quality of life for patients with psoriasis. Dermatology 2007; 215: 17-27.
5. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
6. Kirby B, Richards HL, Woo P, et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001; 45: 72-6.
7. Zachariae R, Zachariae H, Blomqvist K, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002; 146: 1006-16.
8. Sampogna F, Sera F, Abeni D,. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004; 122: 602-7.
9. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-92.
10. Garduno J, Bhosle MJ, Balkrishnan R, et al. Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review. J Dermatolog Treat 2007; 18: 223-42.
11. Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 17-22.
12. Both H, Essink-Bot ML, Busschbach J, et al. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007; 127: 2726-39.
13. Lewis V, Finlay AY,. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 169-80.
14. Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71.
15. Basra MK, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997-1035.
16. Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008; 24: 244-58; discussion 362-8.
17. Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002; 46: 850-60.
18. Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006; 212: 137-44.
19. Ghatnekar O, Ljungberg A, Lundqvist T, et al. Cost of illness of psoriasis-a 1-month prospective study in southern Sweden. Value Health 2010; 13: A239-50 (Abstract).
20. Hjortsberg C, Bergman A, Bjarnason A, et al. Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from Finnish and Swedish patients with psoriasis Acta Derm Venereol (Stockh) 2011; 91: 409-14.
21. Schmitt-Egenolf M,. Psoriasis therapy in real life: the need for registries. Dermatology 2006; 213: 327-30.
22. Schmitt-Egenolf M,. PsoReg-the Swedish registry for systemic psoriasis treatment. The registry's design and objectives. Dermatology 2007; 214: 112-17.
23. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208.
24. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
25. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
26. Burstrom K, Johannesson M, Diderichsen F,. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001; 10: 621-35.
27. Dolan P,. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-108.
28. Swinscow TDV, Campbell MJ,. Statistics at Square One, 9th edn. London: BMJ, 1996.
29. Verbeek M,. A Guide to Modern Econometrics, 3rd edn. Chippenham: John Wiley & Sons, 2008.
30. Lloyd A, Reeves P, Conway P,. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br J Dermatol 2009; 160: 380-7.
31. Blank PR, Blank AA, Szucs TD,. Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema-a long-term analysis from a Swiss perspective. BMC Dermatol 2010; 10: 4.
32. Revicki DA, Menter A, Feldman S, et al. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled phase III study. Health Qual Life Outcomes 2008; 6: 75.
33. Wahl A, Loge JH, Wiklund I, et al. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 2000; 43: 803-8.
34. Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512-18.
35. Augustin M, Krüger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-72.
36. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006; 10: 1-233, i- iv.
37. Brazier JE, Yang Y, Tsuchiya A, et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2010; 11: 215-25.